Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
48.59
-0.53 (-1.09%)
Streaming Delayed Price
Updated: 1:27 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
Today 9:40 EST
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Lawsuit
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
The Tariff Paradox: How Trump's 'Liberation Day' Protectionism Sparked a $2.3 Trillion M&A Feeding Frenzy
January 13, 2026
As of mid-January 2026, the American economic landscape is witnessing a phenomenon few analysts predicted a year ago. Despite the sweeping protectionist measures introduced under President Trump’s...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...
Via
MarketMinute
Topics
Economy
Intellectual Property
World Trade
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
January 09, 2026
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...
Via
MarketMinute
Topics
Intellectual Property
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...
Via
PredictStreet
Topics
Initial Public Offering
Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs
↗
January 08, 2026
Via
Stocktwits
Topics
Government
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
January 07, 2026
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
January 07, 2026
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...
Via
PredictStreet
Topics
Economy
Initial Public Offering
Intellectual Property
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK
↗
January 06, 2026
In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every...
Via
Benzinga
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child
↗
January 05, 2026
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.
Via
Stocktwits
Topics
Government
Flu Season's Here—This Dividend-Payer Controls the Shot Market
↗
January 05, 2026
Via
MarketBeat
Topics
Artificial Intelligence
Death
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report
↗
December 31, 2025
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.
Via
Stocktwits
Topics
Economy
Government
Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market
December 30, 2025
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)...
Via
MarketMinute
Topics
Product Recall
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook
↗
December 30, 2025
The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.
Via
Stocktwits
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
December 26, 2025
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a...
Via
PredictStreet
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
December 25, 2025
Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...
Via
PredictStreet
Topics
Economy
Intellectual Property
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
December 25, 2025
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...
Via
PredictStreet
Topics
Artificial Intelligence
Economy
Intellectual Property
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
December 24, 2025
As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...
Via
PredictStreet
Topics
Initial Public Offering
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
December 24, 2025
As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...
Via
PredictStreet
Topics
Artificial Intelligence
Economy
Intellectual Property
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
December 24, 2025
Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...
Via
PredictStreet
Topics
Economy
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
December 24, 2025
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...
Via
MarketMinute
Topics
Intellectual Property
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk
↗
December 23, 2025
Via
Stocktwits
Topics
Government
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
December 22, 2025
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...
Via
PredictStreet
Topics
Economy
Intellectual Property
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
December 22, 2025
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...
Via
PredictStreet
Topics
Earnings
Initial Public Offering
Intellectual Property
GSK PLC-SPON ADR (NYSE:GSK) Shows Strong Technical Setup for Potential Breakout
↗
December 20, 2025
GSK stock shows strong technical strength and a high-quality setup, signaling a potential breakout for trend-focused investors.
Via
Chartmill
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants
↗
December 19, 2025
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.
Via
Stocktwits
Topics
Government
World Trade
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
December 16, 2025
From
GSK plc
Via
Business Wire
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
December 12, 2025
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Economy
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
December 11, 2025
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
